Philikos
Developing T-Guard, a therapy designed to safely reset the immune system for patients with severe autoimmune diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
* | N/A | Early VC | |
| Total Funding | 000k | ||
Related Content
Philikos is a biotechnology company dedicated to transforming the treatment of severe immune disorders, with a particular focus on systemic sclerosis (scleroderma). Headquartered in Nijmegen, The Netherlands, Philikos is pioneering the development of T-Guard, an innovative therapy designed to rapidly and safely reset the immune system, thereby restoring normal function and offering patients a healthier long-term outlook.
T-Guard is a combination of two toxin-conjugated antibodies that target and transiently deplete activated autoreactive T cells and natural killer (NK) cells, which are key players in the pathogenesis of systemic sclerosis. By selectively eliminating these cells, T-Guard aims to rebalance the immune system more effectively and with a potentially better benefit-risk profile than traditional treatments such as hematopoietic stem cell transplantation (HSCT).
Philikos collaborates with leading academic institutions to advance the clinical development of T-Guard. Notably, the Radboud University Medical Center (Radboudumc) in Nijmegen serves as a participating site for the Proof of Principle (PoP) study. Radboudumc has been at the forefront of systemic sclerosis research since 1988 and is recognized as a national referral center, treating over one-third of all Dutch systemic sclerosis patients.
Philikos is committed to maintaining the highest standards of patient privacy and data protection. The company adheres to stringent privacy policies to ensure that personal data collected during clinical trials and through its website is handled with the utmost care and in compliance with applicable regulations.
Keywords: Philikos, biotechnology company, Nijmegen, The Netherlands, T-Guard, systemic sclerosis, scleroderma, immune system reset, toxin-conjugated antibodies, activated T cells, natural killer cells, Radboud University Medical Center, Radboudumc, Proof of Principle study, hematopoietic stem cell transplantation alternative, patient privacy, data protection.